Reduced Na+/K+ adenosine triphosphatase activity and motor nerve conduction velocity in L-fucose-fed rats is reversible after dietary normalization

Metabolism: Clinical and Experimental

Volumn 45, Issue 2, 1996, Pages 229-234

  Yorek, Mark A ^a,b   Wiese, Thomas J ^a   Davidson, Eric P ^a   Dunlap, Joyce A ^a   Conner, Corinne E ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); FUCOSE; INOSITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIETARY INTAKE; ENZYME ACTIVITY; MALE; MOTOR NERVE CONDUCTION; NERVE FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE;

EID: 0029940163     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90059-1     Document Type: Article

References (38)

1. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316:599-605, 1987
2. Winegrad AI: Does a common mechanism induce the diverse complications of diabetes? Diabetes 36:396-406, 1987
3. Tomlinson DR, Willars GB, Carrington AL: Aldose reductase inhibitors and diabetic complications. Pharmacol Ther 54:151-194, 1992
4. Cameron NE, Cotter MA, Dines KC, et al: Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37:651-663, 1994
5. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94:853-859, 1994
6. Clements RS Jr, Stockard CR: Abnormal sciatic nerve myo-inositol metabolism in the streptozotocin-diabetic rat. Diabetes 29:227-235, 1980
7. Gillon KRW, Hawthorne JN: Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats. Biochem J 210:775-781, 1983
8. +-ATPase, conduction and myo-inositol in the insulin deficient BB-rat. Am J Physiol 247:E534-E539, 1984
9. Gillon KRW, Hawthorne JN, Tomlinson DR: myo-Inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: The effect of aldose reductase inhibition. Diabetologia 25:365-371, 1983
10. Greene DA, Lattimer SA: Action of sorbinil in diabetic peripheral nerve. Diabetes 33:712-716, 1984
11. Tomlinson DR, Moriarty RJ, Mayer JH: Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil. Diabetes 33:470-476, 1984
12. +-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Diabetes 35:1106-1108, 1986
13. +-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 37:688-693, 1988
14. Hirata Y, Fujimori S, Okada K: Effect of a new aldose reductase inhibitor, 8′ chloro-2′, 3′ dihydrospiro [pyrrolidine-3, 6′ (5′H)-pyrrolol [1, 2, 3-de][1,4] benzoxazine]-2, 5, 5′-trione in streptozotocin-diabetic rats. Metabolism 37:159-163, 1988
15. +-ATPase activity in isolated membrane fraction from sciatic nerves of streptozotocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro. Diabetes 40:558-567, 1991
16. Kato K, Nakayama K, Ohta M, et al: Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocininduced diabetic neuropathy in rats. Eur J Pharmacol 193:185-191, 1991
17. Mizuno K, Kato N, Matsubara A, et al: Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′, 5′-dioxospiro [chroman-4, 4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 41:1081-1086, 1992
18. +-ATPase activity in rats maintained on L-fucose diet. Diabetes 42:1401-1406, 1993
19. Sirakor LM: Serum fucose levels in diabetic patients. Acta Diabetol Lat 8:949-956, 1971
20. Radhakrishnamurthy B, Berenson GS, Pargaonkar PS, et al: Serum free and protein-bound sugars and cardiovascular complications in diabetes mellitus. Lab Invest 34:159-165, 1976
21. Yorek MA, Stefani MR, Dunlap JA, et al: trans-Hydroxyl group configuration on carbons 2 and 3 of glucose: Responsible for acute inhibition of myo-inositol transport? Diabetes 40:1016-1023, 1991
22. Yorek MA, Dunlap JA, Stefani MR, et al: L-Fucose is a potent inhibitor of myo-inositol transport and metabolism in cultured neuroblastoma cells. J Neurochem 58:1626-1636, 1992
23. Stefani MR, Dunlap JA, Yorek MA: Effect of L-fucose on proliferation and myo-inositol metabolism in cultured cerebral microvessel and aortic endothelial cells. J Cell Physiol 153:321-331, 1992
24. Djurdjic V, Mandic L: A spectrophotometric method for simultaneous determination of protein-bound hexoses and fucose with a mixture of L-cysteine and phenol. Anal Biochem 188:222-227, 1990
25. Cohenford MA, Abraham A, Abraham J, et al: Colorimetric assay for free and bound L-fucose. Anal Biochem 177:172-177, 1989
26. Mayer JH, Tomlinson DR: Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocindiabetic rats. Diabetologia 25:433-438, 1983
27. Greene DA, Lattimer SA: Impaired rat sciatic nerve sodiumpotassium ATPase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. J Clin Invest 72:1058-1063, 1983
28. Robertson S, Cameron NE, Cotter MA: The effect of the calcium antagonist nifedipine on peripheral nerve function in streptozotocin-diabetic rats. Diabetologia 35:1113-1117, 1992
29. Cotter MA, Dines KC, Cameron NE: Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Arch Pharm (Weinheim) 347:535-540, 1993
30. Maxfield EK, Cameron NE, Cotter MA, et al: Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocindiabetic rats and nerve function. Diabetologia 36:1230-1237, 1993
31. Cameron NE, Cotter MA, Dines KC, et al: Pharmacological manipulation of vascular endothelium function in non-diabetic and streptozotocin-diabetic rats: Effects on nerve conduction, hypoxic resistance and endoneurial capillarization. Diabetologia 36:516-522, 1993
32. Stevens EJ, Lockett MJ, Carrington AL, et al: Essential fatty acid treatment prevents nerve ischaemia and associated conduction anomalies in rats with experimental diabetes mellitus. Diabetologia 36:397-401, 1993
33. Cameron NE, Cotter MA, Archibald V, et al: Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocindiabetic rats. Diabetologia 37:449-459, 1994
34. Greene DA, Chakrabarti S, Lattimer SA, et al: Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic Bio-breeding rat. J Clin Invest 79:1479-1485, 1987
35. + pump in streptozotocin-diabetic rats. Diabetes Metab Rev 8:67-84, 1992
36. + ATPase activity. J Clin Invest 77:503-513, 1986
37. +)-ATPase inhibition in aortic wall of rabbits. Diabetologia 32:402-408, 1989
38. + pump activity and resting membrane potential by myo-inositol supplementation in neuroblastoma cells chronically exposed to glucose or galactose. Diabetes 40:240-248, 1991